newsfilter
← Latest News
Earnings Call Transcripts·

STIFEL 2026 HEALTHCARE CONFERENCE - Zymeworks Inc.

ZYME

  • Explicit Guidance:

    • Royalty Income: Anticipated royalty income from Jazz (Zanidatamab) ranging between $500 million and $900 million annually, derived from Jazz's updated peak sales guidance of $3 billion to $5 billion.
    • Future Revenue: Expectation of continued growth in royalty income from Zanidatamab extending beyond the current period into future years as sales mature.
    • Capital Allocation (R&D): Core R&D funding maintained at a level 20% lower than the previous year but described as "still a pretty substantial commitment."
    • Capital Allocation (Buybacks): No specific dollar amount or share count guidance for future years; strategy described as "opportunistic" with a commitment to return capital regularly, citing 14 million shares bought back (approx. 20% of the company) over the past two years.
    • Capital Allocation (M&A): No specific CapEx or M&A budget guidance; intent to be "opportunistic" with M&A beyond the TheraVance acquisition, potentially utilizing funds from the $55 million upfront payment expected from Roche in December.

  • Business-Segment Outlook:

    • Zanidatamab (GEA): Launch in the U.S. is ongoing with Jazz; anticipated to provide a median OS benefit of eight months for patients; potential for long-term durable survival in a subset of the population.
    • ZW191 (ADC): Data presented at ESMO shows a >70% Objective Response Rate (ORR) in the Mervituximab label indication (vs. 40% benchmark); plan to seek a strategic partner rather than self-develop due to competitive landscape.
    • ZW220 (ADC): Program for gynecological tumors targeting NAPI has been halted at IND stage.
    • ZW251 (HCC): Development continues for GPC3-targeting ADC in Hepatocellular Carcinoma; potential for first-line combination therapy with immunotherapy; less competitive landscape noted compared to ZW191.
    • ZW209 (SCLC): Partnership with Roche established; potential evolution into combination therapies involving T-cell engagers and immunotherapy for Small Cell Lung Cancer; no definitive stage-gate for commercialization given, but partnership ensures accelerated development.
    • Pan-RAS ADC Platform: Four development candidates identified; strategy to spin out a portion of this portfolio with financial investors to preserve unencumbered status while securing equity and royalty stakes.
    • Tri-Specific Engineering: Upcoming scientific disclosures at ASH featuring a penta-specific antibody (5-arm) for AML using the CoSTIM platform; continuous innovation in tri-specific PD-1/VEGF/IL-7.
    • TheraVance Acquisition: Acquired product Aperly is being co-promoted with Beatrice; expected to add to the top line.
    • R&D Pipeline: Continuous generation of unique, differentiated assets (e.g., CD3 bispecifics, CD28 signals) that may be pursued via self-funding, one-off partnerships, or spin-outs.

  • Market and Competitive Outlook:

    • Competitive Environment (ADCs): Anticipates a "flood" of competitors in gynecological tumors with unselected patient populations, making self-funded development of ZW191 economically unfavorable; differentiation via receptor alpha expression targeting is key.
    • Platform Differentiation: No other players currently executing penta-specific antibodies or the specific tri-specific PD-1/VEGF/IL-7 format; CoSTIM platform viewed as unique in combining T-cell signals within a single biologic structure.
    • M&A Landscape: Identifies a "mispriced opportunity" niche where Zymorx can acquire assets (like TheraVance) based on internal R&D and tax attribute upside that traditional acquirers may not value, potentially achieving mid-teens IRR on acquisitions.
    • Partnership Dynamics: Moving away from binary "all-or-nothing" self-funding; anticipating more partnerships to share risk and capitalize on capital intensity, particularly for assets requiring combination regimens (e.g., ZW209).

  • Macro / Industry Outlook:

    • Valuations: Observes that valuations for early-stage assets are "pretty healthy," suggesting a potential ceiling where generating additional clinical data may not proportionally increase transaction value.
    • Capital Constraints: Acknowledges that traditional balance sheet funding is insufficient for the scale of the current R&D pipeline; industry-wide trend toward capital partnerships and spin-outs to avoid dilution and risk destruction.
    • Regulatory/Timing: Notes that timing of partnerships (e.g., Roche/ZW209) can be strategic, leveraging validation from competitor data (Tarlatamab) to accelerate own programs.

  • Strategic Initiatives:

    • Financing Structure: Execution of a $250 million credit facility against future Zanidatamab royalties with Royalty Pharma; half allocated to stock buybacks, half to the TheraVance acquisition.
    • Spin-Offs: Planning to carve out the Pan-RAS ADC portfolio into a dedicated entity with financial investors, retaining equity and royalty stakes.
    • Acquisitions: TheraVance acquisition serves as a proof-of-concept for opportunistic M&A; future M&A strategy remains flexible (commercial assets, R&D assets, or balance adjustments).
    • R&D Focus: Continued investment in CoSTIM platform engineering, moving from bispecifics to tri-specific and penta-specific structures; no pre-defined cap on R&D spend, described as a "core commitment" adjusted for cash flow and opportunities.
    • Partnership Models: Three-pronged approach: (1) Unencumbered self-funded R&D, (2) Strategic Pharma Partnerships (e.g., Jazz, Roche), (3) Financial Investor Spin-outs.

  • Risks and Headwinds to Outlook:

    • Capital Dilution/Risk: Avoids binary study risks and excessive equity dilution associated with traditional biotech self-funding models.
    • Competitive Intensity: In gynecological tumors, a crowded market may erode the value of self-funded ZW191; partnership is required to de-risk and accelerate.
    • Execution Risk: Future value creation depends on successfully executing the "diversified business model" of balancing R&D, M&A, and capital returns over 2027-2028.
    • Partnership Dependency: Future revenue relies heavily on the commercial success of partners (Jazz, B1, Roche); performance is tied to their execution capabilities.
    • M&A Discipline: Need to avoid overpaying for assets; success requires identifying targets where the acquirer can unlock specific R&D or tax value others cannot.

  • Management Tone on the Future:

    • Confidence: "Pretty excited," "Encouraged," and "Gratified" regarding the transition from a pure-play R&D model to a diversified platform that monetizes assets while retaining upside.
    • Strategic Clarity: Emphasizes "financial discipline" and "optionality"; explicitly rejects "traditional biotech dogma" of forward integration into sales.
    • Long-Term View: Focus on "long-term durable survival benefit" for patients and "long-term total shareholder return" through a mix of royalties, buybacks, and M&A, with a specific timeline of executing the same momentum in 2027 and 2028.
    • Adaptability: Willing to pivot strategies (e.g., selling ZW191) based on competitive dynamics and capital efficiency, prioritizing shareholder value preservation over "going it alone."

  • Miscellaneous:

    • Shareholder Return Strategy: Belief that returning capital to shareholders is "a good thing for biotechs," supported by a "diversified business model" that allows for both R&D growth and capital return.
    • Valuation Philosophy: Views current stock price as attractive relative to underlying value, evidenced by the decision to buy back 20% of the company over two years.
    • Scientific Milestones: Upcoming ASH presentation on a penta-specific antibody; recent CITSE disclosures on tri-specific engineering; continued focus on novel targets (GPC3, RAS) and platforms (CoSTIM).
    • TheraVance IRR: Base case IRR relies on "modest growth" in Aperly sales; upside driven by utilization of existing R&D assets, licenses, and tax attributes.